Retro Biosciences has leveraged a bespoke AI model, developed in collaboration with OpenAI, to enhance stem cell protein design. The AI's ability to optimise these proteins has led to marked improvements in cellular reprogramming efficiency, a process vital for reversing cellular ageing.
Cellular reprogramming involves converting specialised cells back into a pluripotent state, similar to that of embryonic stem cells. These rejuvenated cells can then be differentiated into various cell types, offering potential therapeutic applications in regenerative medicine and age-related diseases. The enhanced efficiency achieved through AI-designed proteins represents a significant step forward in making cellular reprogramming a more viable and scalable approach.
This advancement not only accelerates research into longevity therapies but also highlights the transformative potential of AI in biotechnology. By automating and optimising complex protein design, AI can significantly reduce the time and resources required for developing new treatments, paving the way for future breakthroughs in combating ageing and disease.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
